Drug-Drug Compatibility Studies of Novel Combination of Drugs for the Treatment of Irritable Bowel Syndrome

Abstract

Irritable bowel syndrome (IBS) has become a disorder of concern which affects the large intestine. Symptoms observed includes abdominal pain, cramping, bloating gas, and diarrhoea or constipation, or both. IBS is chronic and needs to manage for long term. Infection caused by bacteria or a virus needs to treat with an antibiotic and other relief of symptoms including intestinal discomfort, bowel disturbances and abdominal pain; are to be treated with antispasmodic. This, urged to design a new drug delivery system that would efficiently release Rifaximin and Pinaverium bromide, in a target specific site to lessen the adverse effects and dosing frequency, when administered in combination. However, certain combinations of drugs may pose safety concerns due to interactions. Thus, the current study was designed to evaluate the interaction of Rifaximin and Pinaverium bromide to develop a combo nano drug delivery system. Thermal stressing and characterization performed to evaluate the interactions of drugs in combination. Rifaximin and Pinaverium bromide combination shown to be stable without any significant physico chemical interactions. This study proved that Rifaximin and Pinaverium bromide is compatible with each other to develop nanoparticle formulations with combination of both drugs.